Serina Therapeutics (SER) director granted 59,667 dividend shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Serina Therapeutics director Bailey Gregory acquired additional common stock through a share award. On March 31, 2026, Gregory received 59,667 shares of Serina Therapeutics common stock at $1.94 per share in a grant classified as a “grant, award, or other acquisition.”
According to a footnote, these shares were issued as payment of accrued dividends on the reporting individual’s Series A Convertible Preferred Stock issued on April 8, 2025. Following this transaction, Gregory directly holds 126,910 shares of Serina Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bailey Gregory
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 59,667 | $1.94 | $116K |
Holdings After Transaction:
Common Stock — 126,910 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Shares acquired: 59,667 shares
Transaction price per share: $1.94 per share
Total shares after transaction: 126,910 shares
3 metrics
Shares acquired
59,667 shares
Grant on March 31, 2026
Transaction price per share
$1.94 per share
Value assigned to granted common stock
Total shares after transaction
126,910 shares
Director’s direct holdings following grant
Key Terms
Grant, award, or other acquisition, Series A Convertible Preferred Stock, accrued dividends
3 terms
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
Series A Convertible Preferred Stock financial
"accrued dividends on the reporting individuals Series A Convertible Preferred Stock"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
accrued dividends financial
"were issued for payment of accrued dividends on the reporting individuals Series A"
Accrued dividends are payments a company owes to shareholders that have been earned or officially declared but not yet paid; think of them as an IOU the company has for past dividend obligations. They matter to investors because they represent a near-term claim on a company’s cash, affect the company’s reported liabilities and value, and can be especially important when assessing income reliability or priority in a payout situation.
FAQ
What insider transaction did Serina Therapeutics (SER) disclose for Bailey Gregory?
Serina Therapeutics reported that director Bailey Gregory acquired 59,667 shares of common stock. The shares were received as a grant labeled “grant, award, or other acquisition,” increasing Gregory’s direct holdings to 126,910 shares of Serina Therapeutics common stock.
Why did Bailey Gregory receive additional Serina Therapeutics (SER) common stock?
The filing states that the shares were issued as payment of accrued dividends on the reporting individual’s Series A Convertible Preferred Stock. That preferred stock was issued on April 8, 2025, and the accrued dividends were settled using newly issued common shares.
Is Bailey Gregory’s Serina Therapeutics (SER) transaction an open-market buy or a grant?
The transaction is reported with code A, described as a “grant, award, or other acquisition,” not an open-market purchase. The shares were issued to pay accrued dividends on Series A Convertible Preferred Stock rather than being bought on the open market.